CONJUGATED ANTIBODIES FOR TREATING DISEASES

1 . An agent comprising:

a human plasma immunoglobulin moiety,

an immune cell surface receptor binding moiety capable of modulating the immune cell surface receptor, and

optionally a linker moiety linking the human plasma immunoglobulin moiety and the immune cell surface receptor binding moiety.

2 . The agent of claim 1 , wherein the immune cell surface receptor is an Fc receptor.

3 . The agent of claim 1 , wherein the immune cell surface receptor is CD16A (FcγRIIIa) or CD32B (FcγRIIb).

4 . The agent of claim 1 , wherein the immune cell surface receptor is NKG2D.

5 . The agent of any one of claims 1 to 4 , wherein the agent has the structure of formula M-1:

or a pharmaceutically acceptable salt thereof, wherein:

a is 1 or 2;

b is 1, 2, or 3;

IG is a human plasma immunoglobulin moiety;

each L is a linker moiety; and

RBM is an immune cell surface receptor binding moiety capable of modulating the immune cell surface receptor,

wherein the human plasma immunoglobulin moiety comprises an immunoglobulin or a fragment thereof from an IVIG preparation.

6 . The agent of any one of claims 1 to 5 , wherein the immunoglobulin moiety comprises IgG1 or a fragment thereof, IgG2 or a fragment thereof, or IgG4 or a fragment thereof.

7 . The agent of any one of claims 1 to 6 , wherein the immunoglobulin moiety comprises IgG1 or a fragment thereof is linked to the linker L, at an amino acid residue selected from K246 and K248 of an IgG1 heavy chain and amino acid residues corresponding thereto; or

the immunoglobulin moiety comprises IgG2 or a fragment thereof IgG2 or a fragment thereof is linked to the linker, at an amino acid residue selected from K251 and K253 of an IgG2 heavy chain and amino acid residues corresponding thereto; or

the immunoglobulin moiety comprises IgG4 or a fragment thereof is linked to the linker, at an amino acid residue selected from K239 and K241 of an IgG4 heavy chain and amino acid residues corresponding thereto.

8 . The agent of any one of claims 5 to 7 , wherein

L is a covalent bond, or a bivalent or polyvalent optionally substituted, linear or branched C 1-100 group comprising one or more aliphatic, aryl, heteroaromatic having 1-20 heteroatoms, or any combinations thereof, wherein one or more methylene units of the group are optionally and independently replaced with C 1-6 alkylene, C 1-6 alkenylene, —C≡C—, -Cy-, —C(R′) 2 —, —O—, —S—S—, —N(R′)—, —C(O)—, —C(S)—, —C(NR′)—, —C(O)N(R′)—, —C(O)C(R′) 2 N(R′)—, —N(R′)C(O)N(R′)—, —N(R′)C(O)O—, —S(O)—, —S(O) 2 —, —S(O) 2 N(R′)—, —C(O)S—, —C(O)O—, —P(O)(OR′)—, —P(O)(SR′)—, —P(O)(R′)—, —P(O)(NR′)—, —P(S)(OR′)—, —P(S)(SR′)—, —P(S)(R′)—, —P(S)(NR′)—, —P(R′)—, —P(OR′)—, —P(SR′)—, —P(NR′)—, an amino acid residue, or -[(—O—C(R′) 2 —C(R′) 2 -) n ]-, wherein n is 1-20;

-Cy- is independently an optionally substituted bivalent monocyclic, bicyclic or polycyclic group wherein each monocyclic ring is independently selected from a C 3-20 cycloaliphatic ring, a C 6-20 aryl ring, a 5-20 membered heteroaryl ring having 1-10 heteroatoms, and a 3-20 membered heterocyclyl ring having 1-10 heteroatoms;

each R′ is independently —R, —C(O)R, —CO 2 R, or —SO 2 R; and

each R is independently —H, or an optionally substituted.

9 . The agent of any one of claims 5 to 8 , wherein the linker comprises one or more —[(CH 2 ) n -0]m-, wherein each n is independently 1-20, and m is 1-100.

10 . A method of treating an acute or chronic inflammatory disorder in a patient in need thereof, comprising administering to the patient a pharmaceutically effective amount of the agent of one of claims 1 to 9 .

11 . A method of treating an acute or chronic autoimmune disorder in a patient in need thereof, comprising administering to the patient a pharmaceutically effective amount of the agent of one of claims 1 to 9 .

12 . A method of treating cancer in a patient in need thereof, comprising administering to the patient a pharmaceutically effective amount of the agent of one of claims 1 to 9 .

13 . An agent comprising:

an hyperimmune globulin moiety,

an immune cell surface receptor binding moiety capable of modulating the immune cell surface receptor, and

optionally a linker moiety linking the hyperimmune globulin moiety and the immune cell surface receptor binding moiety.

14 . The agent of claim 13 , wherein the immune cell surface receptor is CD16A, CD32B, NKG2D, or DC-SIGN.

15 . The agent of claim 13 , wherein the agent has the structure of formula M-II:

or a pharmaceutically acceptable salt thereof, wherein:

a is 1 or 2;

b is 1, 2, or 3;

HG is a hyperimmune globulin moiety;

each L is a linker moiety; and

RBM is an immune cell surface receptor binding moiety capable of modulating the immune cell surface receptor,

wherein the immune cell surface receptor is DC-SIGN.

16 . The agent of claim 14 or 15 , wherein the hyperimmune globulin moiety comprises HIgG1 or a fragment thereof, HIgG2 or a fragment thereof, or HIgG4 or a fragment thereof.

17 . The agent of any one of claims 14 to 16 , wherein the hyperimmune globulin moiety comprises HIgG1 or a fragment thereof that is linked to the linker L, at an amino acid residue selected from K246 and K248 of an HIgG1 heavy chain and amino acid residues corresponding thereto; or

the hyperimmune globulin moiety comprises HIgG2 or a fragment thereof that is linked to the linker, at an amino acid residue selected from K251 and K253 of an HIgG2 heavy chain and amino acid residues corresponding thereto; or

the hyperimmune globulin moiety comprises IgG4 or a fragment thereof that is linked to the linker, at an amino acid residue selected from K239 and K241 of an IgG4 heavy chain and amino acid residues corresponding thereto.

18 . The agent of any one of claims 15 to 17 , wherein

L is a covalent bond, or a bivalent or polyvalent optionally substituted, linear or branched C 1-100 group comprising one or more aliphatic, aryl, heteroaromatic having 1-20 heteroatoms, or any combinations thereof, wherein one or more methylene units of the group are optionally and independently replaced with C 1-6 alkylene, C 1-6 alkenylene, —C—C—, -Cy-, —C(R′) 2 —, —O—, —S—S—, —N(R′)—, —C(O)—, —C(S)—, —C(NR′)—, —C(O)N(R′)—, —C(O)C(R′) 2 N(R′)—, —N(R′)C(O)N(R′)—, —N(R′)C(O)O—, —S(O)—, —S(O) 2 —, —S(O) 2 N(R′)—, —C(O)S—, —C(O)O—, —P(O)(OR′)—, —P(O)(SR′)—, —P(O)(R′)—, —P(O)(NR′)—, —P(S)(OR′)—, —P(S)(SR′)—, —P(S)(R′)—, —P(S)(NR′)—, —P(R′)—, —P(OR′)—, —P(SR′)—, —P(NR′)—, an amino acid residue, or -[(—O—C(R′) 2 —C(R′) 2 -) n ]-, wherein n is 1-20;

-Cy- is independently an optionally substituted bivalent monocyclic, bicyclic or polycyclic group wherein each monocyclic ring is independently selected from a C 3-20 cycloaliphatic ring, a C 6-20 aryl ring, a 5-20 membered heteroaryl ring having 1-10 heteroatoms, and a 3-20 membered heterocyclyl ring having 1-10 heteroatoms;

each R′ is independently —R, —C(O)R, —CO 2 R, or —SO 2 R; and

each R is independently —H, or an optionally substituted.

19 . The agent of any one of claims 15 to 18 , wherein the linker comprises one or more —[(CH 2 ) n —O] m —, wherein each n is independently 1-20, and m is 1-100.

20 . A method of treating an infectious disease in a patient in need thereof, comprising administering to the patient a pharmaceutically effective amount of the agent of one of claims 14 to 19 .

21 . The method of claim 20 , wherein the infectious disease is a viral infection.

22 . The method of claim 21 , wherein the viral infection is influenza.

23 . A method of treating an acute or chronic inflammatory disorder in a patient in need thereof, comprising administering to the patient a pharmaceutically effective amount of the agent of one of claims 14 to 19 .

24 . A method of treating an acute or chronic autoimmune disorder in a patient in need thereof, comprising administering to the patient a pharmaceutically effective amount of the agent of one of claims 14 to 19 .

25 . A method of treating cancer in a patient in need thereof, comprising administering to the patient a pharmaceutically effective amount of the agent of one of claims 14 to 19 .

26 . An agent, wherein the agent has the structure of formula R-L:

LG IG -RG-L RM -RBM,  R—I

or a salt thereof, wherein:

LG IG is R LG -L LG ;

R LG is a moiety capable of binding to a human plasma immunoglobulin with site-directed specificity that is selected from

R c -(Xaa)z-, IVIG, a nucleic acid moiety, and a small molecule moiety;

each Xaa is independently a residue of an amino acid or an amino acid analog;

t is 0-50;

z is 1-50;

each R c is independently -L a -R′;

each of a and b is independently 1-200;

each L a is independently a covalent bond, or an optionally substituted bivalent group selected from C 1 -C 20 aliphatic or C 1 -C 20 heteroaliphatic having 1-5 heteroatoms, wherein one or more methylene units of the group are optionally and independently replaced with —C(R′) 2 —, -Cy-, —O—, —S—, —S—S—, —N(R′)—, —C(O)—, —C(S)—, —C(NR′)—, —C(O)N(R′)—, —N(R′)C(O)N(R′)—, —N(R′)C(O)O—, —S(O)—, —S(O) 2 —, —S(O) 2 N(R′)—, —C(O)S—, or —C(O)O—;

each -Cy- is independently an optionally substituted bivalent monocyclic, bicyclic or polycyclic group wherein each monocyclic ring is independently selected from a C 3-20 cycloaliphatic ring, a C 6-20 aryl ring, a 5-20 membered heteroaryl ring having 1-10 heteroatoms, and a 3-20 membered heterocyclyl ring having 1-10 heteroatoms;

L LG is -L LG1 -, -L LG1 -L LG2 -, -L LG1 -L LG2 -L LG3 -, or -L LG1 -L LG2 -L LG3 -L LG4 -;

RG is -L RG1 -L RG2 -, -L LG4 -L RG1 -L RG2 -, -L LG3 -L LG4 -LRG-L RG2 -, -L LG2 -L LG3 -L LG4 -L RG1 -L RG2 -;

each of L LG1 , L LG2 , L LG3 , L LG4 , L RG1 , L RG2 , and L RM is independently L;

each L is independently a covalent bond, or a bivalent optionally substituted, linear or branched C 1-100 group comprising one or more aliphatic moieties, aryl moieties, heteroaliphatic moieties each independently having 1-20 heteroatoms, heteroaromatic moieties each independently having 1-20 heteroatoms, or any combinations of any one or more of such moieties, wherein one or more methylene units of the group are optionally and independently replaced with C 1-6 alkylene, C 1-6 alkenylene, a bivalent C 1-6 heteroaliphatic group having 1-5 heteroatoms, —C≡C—, -Cy-, —C(R′) 2 —, —O—, —S—, —S—S—, —N(R′)—, —C(O)—, —C(S)—, —C(NR′)—, —C(O)N(R′)—, —C(O)C(R′) 2 N(R′)—, —N(R′)C(O)N(R′)—, —N(R′)C(O)O—, —S(O)—, —S(O) 2 —, —S(O) 2 N(R′)—, —C(O)S—, —C(O)O—, —P(O)(OR′)—, —P(O)(SR′)—, —P(O)(R′)—, —P(O)(NR′)—, —P(S)(OR′)—, —P(S)(SR′)—, —P(S)(R′)—, —P(S)(NR′)—, —P(R′)—, —P(OR′)—, —P(SR′)—, —P(NR′)—, an amino acid residue, or -[(—O—C(R′) 2 —C(R′) 2 -) n ]-, wherein n is 1-20;

each R′ is independently —R, —C(O)R, —CO 2 R, or —SO 2 R;

each R is independently —H, or an optionally substituted group selected from C 1-30 aliphatic, C 1-30 heteroaliphatic having 1-10 heteroatoms, C 6-30 aryl, C 6-30 arylaliphatic, C 6-30 arylheteroaliphatic having 1-10 heteroatoms, 5-30 membered heteroaryl having 1-10 heteroatoms, and 3-30 membered heterocyclyl having 1-10 heteroatoms, or

two R groups are optionally and independently taken together to form a covalent bond, or:

two or more R groups on the same atom are optionally and independently taken together with the atom to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the atom, 0-10 heteroatoms; or

two or more R groups on two or more atoms are optionally and independently taken together with their intervening atoms to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the intervening atoms, 0-10 heteroatoms; and

RBM is a cell surface receptor binding moiety capable of modulating the cell surface receptor,

wherein the cell surface receptor is CD16, CD32, or NKG2.

27 . The agent of claim 26 , wherein LG IG comprises or has the structure of

(i) DCAWHLGELVWCT or a salt form thereof, wherein the two C residues are linked by a —S—S—;

(ii) DCAWHLGELVWCT or a salt form thereof, wherein the N-terminus is capped with R—C(O)—; or

(iii) DCAWHLGELVWCT or a salt form thereof, wherein the N-terminus is capped with R—C(O)—, wherein R is methyl; or

(iv) DCAWHLGELVWCT or a salt form thereof, wherein the antibody binding moiety is connected to the rest of a molecule through its C-terminus.

28 . The agent of claim 26 , wherein LG IG comprises or has the structure selected from A-1 to A-50, or a salt form thereof.

29 . The agent of any one of claims 26-28 , wherein each L is independently a covalent bond, or a bivalent optionally substituted, linear or branched aliphatic group or heteroaliphatic group having 1-10 heteroatoms, wherein one or more methylene units of the group are optionally and independently replaced with —C≡C—, -Cy-, —C(R′) 2 —, —O—, —S—, —S—S—, —N(R′)—, —C(O)—, —C(S)—, —C(NR′)—, —C(O)N(R′)—, —C(O)C(R′) 2 N(R′)—, —N(R′)C(O)N(R′)—, —N(R′)C(O)O—, —S(O)—, —S(O) 2 —, —S(O) 2 N(R′)—, —C(O)S—, —C(O)O—, —P(O)(OR′)—, —P(O)(SR′)—, —P(O)(R′)—, —P(O)(NR′)—, —P(S)(OR′)—, —P(S)(SR′)—, —P(S)(R′)—, —P(S)(NR′)—, —P(R′)—, —P(OR′)—, —P(SR′)—, —P(NR′)—, an amino acid residue, or -[(—O—C(R′) 2 —C(R′) 2 -) n ]-, wherein n is 1-20.

30 . The agent of any one of claims 26-29 , wherein

LG IG is R LG -L LG -, wherein R LG is or comprises a target binding moiety and L LG is L LG1 , L LG1 -L LG2 -, L LG1 -L LG2 -L LG3 -, or L LG1 -L LG2 -L LG3 -L LG4 -, wherein each L LG is independently chosen from L.

31 . The agent of any one of claims 26-30 , wherein RG is or comprises -L LG2 -L LG3 -L LG4 -L RG1 -L RG1 -, -L LG2 -L LG3 -L LG4 -L RG1 -L RG2 -, -L LG3 -L LG4 -L RG1 -L RG2 -L LG4 -L RG1 -L RG2 -, or -L RG1 -L RG2 -, wherein L LG1 is a covalent bond, —(CH 2 CH 2 O) n —, or —(CH 2 ) n —O—(CH 2 CH 2 O) n —(CH 2 ) n —;

L LG2 is or comprises a covalent bond, —NR′—, —C(O)—, —NR′C(O)—, —(CH 2 ) n —OC(O)N(R′)—, —CH 2 N(CH 2 CH 2 CH 2 S(O) 2 OH)—C(O)—, —C(O)—NHCH 2 —, —C(O)O—CH 2 —, or —NH—C(O)O—CH 2 —;

R′ is H or C 1 -C 6 alkyl;

L LG3 is optionally bonded to —C(O)— and L LG3 a covalent bond or a substituted phenyl ring, substituted with one or more substituents, and one or more substituents are independently an electron-withdrawing group;

L LG3 is

where R s is F or NO 2 ;

L LG4 is a covalent bond, —O—, —NR′—;

L RG1 is a covalent bond, —S(O) 2 — or —C(O)—;

L RG2 is or comprises —C(O)—, —C(O)O—, —C(O)N(R′)—, —S(O)—, —S(O) 2 —, —P(O)(OR′)—, —P(O)(SR′)—, or —P(O)(N(R′) 2 )—;

wherein each n is independently 1-10, and each —CH 2 — is independently optionally substituted.

32 . The agent of any one of claims 26-31 , wherein L LG3 is

and wherein each R 5 is F or NO 2 .

33 . The agent of any one of claims 26-32 , wherein L RG2 is or comprises -L RG3 -C(═CR RG1 R RG2 )—CR RG3 R RG4 — or -L RG3 -C(═CHR RG2 )—CHR RG4 —, wherein each of R RG1 , R RG2 , R RG3 and R RG4 is independently -L-R′, and L RG3 is —C(O)—, —C(O)O—, —C(O)N(R′)—, —S(O)—, —S(O) 2 —, —P(O)(OR′)—, —P(O)(SR′)—, or —P(O)(N(R′) 2 )—.

34 . The agent of any one of claims 26-33 , wherein -L LG2 -L LG3 -L LG4 -L RG1 - is a structure selected from:

35 . An agent, wherein the agent has the structure of formula R-II:

LG HG -RG-L RM -RBM,  R-II

or a salt thereof, wherein:

LG HG is R LG -L LG ;

R G is a moiety capable of binding to a human plasma immunoglobulin with site-directed specificity that is selected from

R c -(Xaa)z-, IVIG, a nucleic acid moiety, and a small molecule moiety;

each Xaa is independently a residue of an amino acid or an amino acid analog;

t is 0-50;

z is 1-50;

each R c is independently -L a -R′;

each of a and b is independently 1-200;

each L a is independently a covalent bond, or an optionally substituted bivalent group selected from C 1 -C 20 aliphatic or C 1 -C 20 heteroaliphatic having 1-5 heteroatoms, wherein one or more methylene units of the group are optionally and independently replaced with —C(R′) 2 —, -Cy-, —O—, —S—, —S—S—, —N(R′)—, —C(O)—, —C(S)—, —C(NR′)—, —C(O)N(R′)—, —N(R′)C(O)N(R′)—, —N(R′)C(O)O—, —S(O)—, —S(O) 2 —, —S(O) 2 N(R′)—, —C(O)S—, or —C(O)O—;

each -Cy- is independently an optionally substituted bivalent monocyclic, bicyclic or polycyclic group wherein each monocyclic ring is independently selected from a C 3-20 cycloaliphatic ring, a C 6-20 aryl ring, a 5-20 membered heteroaryl ring having 1-10 heteroatoms, and a 3-20 membered heterocyclyl ring having 1-10 heteroatoms;

L LG is -L LG1 -, -L LG1 -L LG2 -, -L LG1 -L LG2 -L LG3 -, or -L LG1 -L LG2 -L LG3 -L LG4 -;

RG is -L RG1 -L RG2 -, -L LG4 -L RG1 -L RG2 -, -L LG3 -L LG4 -LRG-L RG2 -, -L LG2 -L LG3 -L LG4 -L RG1 -L RG2 -;

each of L LG1 , L LG2 , L LG3 , L LG4 , L RG1 , L RG2 , and L RM is independently L;

each L is independently a covalent bond, or a bivalent optionally substituted, linear or branched C 1-100 group comprising one or more aliphatic moieties, aryl moieties, heteroaliphatic moieties each independently having 1-20 heteroatoms, heteroaromatic moieties each independently having 1-20 heteroatoms, or any combinations of any one or more of such moieties, wherein one or more methylene units of the group are optionally and independently replaced with C 1-6 alkylene, C 1-6 alkenylene, a bivalent C 1-6 heteroaliphatic group having 1-5 heteroatoms, —C≡C—, -Cy-, —C(R′) 2 —, —O—, —S—, —S—S—, —N(R′)—, —C(O)—, —C(S)—, —C(NR′)—, —C(O)N(R′)—, —C(O)C(R′) 2 N(R′)—, —N(R′)C(O)N(R′)—, —N(R′)C(O)O—, —S(O)—, —S(O) 2 —, —S(O) 2 N(R′)—, —C(O)S—, —C(O)O—, —P(O)(OR′)—, —P(O)(SR′)—, —P(O)(R′)—, —P(O)(NR′)—, —P(S)(OR′)—, —P(S)(SR′)—, —P(S)(R′)—, —P(S)(NR′)—, —P(R′)—, —P(OR′)—, —P(SR′)—, —P(NR′)—, an amino acid residue, or -[(—O—C(R′) 2 —C(R′) 2 -) n ]-, wherein n is 1-20;

each R′ is independently —R, —C(O)R, —CO 2 R, or —SO 2 R;

each R is independently —H, or an optionally substituted group selected from C 1-30 aliphatic, C 1-30 heteroaliphatic having 1-10 heteroatoms, C 6-30 aryl, C 6-30 arylaliphatic, C 6-30 arylheteroaliphatic having 1-10 heteroatoms, 5-30 membered heteroaryl having 1-10 heteroatoms, and 3-30 membered heterocyclyl having 1-10 heteroatoms, or

two R groups are optionally and independently taken together to form a covalent bond, or:

two or more R groups on the same atom are optionally and independently taken together with the atom to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the atom, 0-10 heteroatoms; or

two or more R groups on two or more atoms are optionally and independently taken together with their intervening atoms to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the intervening atoms, 0-10 heteroatoms; and

RBM is a cell surface receptor binding moiety capable of modulating the cell surface receptor,

wherein the cell surface receptor is DC-SIGN.

36 . The agent of claim 35 , wherein LG HG comprises or has the structure of

(i) DCAWHLGELVWCT or a salt form thereof, wherein the two C residues are linked by a —S—S—;

(ii) DCAWHLGELVWCT or a salt form thereof, wherein the N-terminus is capped with R—C(O)—; or

(iii) DCAWHLGELVWCT or a salt form thereof, wherein the N-terminus is capped with R—C(O)—, wherein R is methyl; or

(iv) DCAWHLGELVWCT or a salt form thereof, wherein the antibody binding moiety is connected to the rest of a molecule through its C-terminus.

37 . The agent of claim 36 , wherein LG HG comprises or has the structure selected from A-1 to A-50, or a salt form thereof.

38 . The agent of any one of claims 35-37 , wherein each L is independently a covalent bond, or a bivalent optionally substituted, linear or branched aliphatic group or heteroaliphatic group having 1-10 heteroatoms, wherein one or more methylene units of the group are optionally and independently replaced with —C≡C—, -Cy-, —C(R′) 2 —, —O—, —S—, —S—S—, —N(R′)—, —C(O)—, —C(S)—, —C(NR′)—, —C(O)N(R′)—, —C(O)C(R′) 2 N(R′)—, —N(R′)C(O)N(R′)—, —N(R′)C(O)O—, —S(O)—, —S(O) 2 —, —S(O) 2 N(R′)—, —C(O)S—, —C(O)O—, —P(O)(OR′)—, —P(O)(SR′)—, —P(O)(R′)—, —P(O)(NR′)—, —P(S)(OR′)—, —P(S)(SR′)—, —P(S)(R′)—, —P(S)(NR′)—, —P(R′)—, —P(OR′)—, —P(SR′)—, —P(NR′)—, an amino acid residue, or -[(—O—C(R′) 2 —C(R′) 2 -) n ]-, wherein n is 1-20.

39 . The agent of any one of claims 35-38 , wherein

LG HG is R LG -L LG -, wherein R LG is or comprises a target binding moiety and L LG is L LG1 , L LG1 -L LG2 -, L LG1 -L LG2 -L LG3 -, or L LG1 -L LG2 -L LG3 -L LG4 -, wherein each L LG is independently chosen from L.

40 . The agent of any one of claims 35-39 , wherein RG is or comprises -L LG2 -L LG3 -L LG4 -L RG1 -L RG1 -, -L LG2 -L LG3 -L LG4 -L RG1 -L RG2 -, -L LG3 -L LG4 -L RG1 -L RG2 -, L LG4 -L RG1 -L RG2 -, or -L RG1 -L RG2 -, wherein

L LG1 is a covalent bond, —(CH 2 CH 2 O) n —, or —(CH 2 ) n —O—(CH 2 CH 2 O) n —(CH 2 ) n —;

L LG2 is or comprises a covalent bond, —NR′—, —C(O)—, —NR′C(O)—, —(CH 2 ) n —OC(O)N(R′)—, —CH 2 N(CH 2 CH 2 CH 2 S(O) 2 OH)—C(O)—, —C(O)—NHCH 2 —, —C(O)O—CH 2 —, or —NH—C(O)O—CH 2 —;

R′ is H or C 1 -C 6 alkyl;

L LG3 is optionally bonded to —C(O)— and L LG3 a covalent bond or a substituted phenyl ring, substituted with one or more substituents, and one or more substituents are independently an electron-withdrawing group;

L LG3 is

where R s is F or NO 2 ;

L LG4 is a covalent bond, —O—, —NR′—;

L RG1 is a covalent bond, —S(O) 2 — or —C(O)—;

L RG2 is or comprises —C(O)—, —C(O)O—, —C(O)N(R′)—, —S(O)—, —S(O) 2 —, —P(O)(OR′)—, —P(O)(SR′)—, or —P(O)(N(R′) 2 )—;

wherein each n is independently 1-10, and each —CH 2 — is independently optionally substituted.

41 . The agent of any one of claims 35-40 , wherein L LG3 is

and wherein each R s is F or NO 2 .

42 . The agent of any one of claims 35-41 , wherein L RG2 is or comprises -L RG3 -C(═CR RG1 R RG2 )—CR RG3 R RG4 — or -L RG3 -C(═CHR RG2 )—CHR RG4 —, wherein each of R RG1 , R RG2 , R RG3 and R RG4 is independently -L-R′, and L RG3 is —C(O)—, —C(O)O—, —C(O)N(R′)—, —S(O)—, —S(O) 2 —, —P(O)(OR′)—, —P(O)(SR′)—, or —P(O)(N(R′) 2 )—.

43 . The agent of any one of claims 35-42 , wherein -L LG2 -L LG3 -L LG4 -L RG1 - is a structure selected from: